Could Half the Dose Work Just as Well for Thalassemia Patients?

Scientists in India just finished a major study that could change how doctors treat a blood condition called transfusion-dependent thalassemia. This illness forces patients to rely on regular blood transfusions to stay healthy. The research team wanted to find out if a drug called thalidomide could help cut down on how many transfusions people actually need.

The study took place across four different hospitals in India. Researchers split 188 patients into two groups. One group received a daily dose of 1 milligram per kilogram of body weight. The other group got double that amount at 2 milligrams per kilogram. Everyone taking part was at least 12 years old and had been dependent on regular transfusions. Scientists tracked how well each dose worked over a 24-week period.

Here is what surprised the team. The patients taking the lower dose actually responded better overall. About 67 percent of those on 1mg showed improvement, compared to only half of the patients receiving the higher 2mg dose. The overall response rate across both groups reached nearly 59 percent. Most patients fell into the moderate improvement category, meaning their transfusion needs dropped between 25 and 50 percent. Nine patients in the entire study stopped needing transfusions altogether.

Speed matters too. Among patients who saw the best results, more than 70 percent noticed changes within just three months. Every single patient with moderate improvements felt the benefits in that same timeframe. The researchers continued watching participants through week 72 to see if the benefits stuck around. When they gradually reduced the medication dose, about half of the original responders maintained their improvements.

Safety played a big role in the findings. Most side effects reported were mild, with only about 11 percent of participants quitting the study because of drug reactions. This matters because thalidomide has a troubled history with serious birth defects. The study shows that starting with the lower dose might give the same results with fewer risks. For hospitals and clinics with limited resources, using less medication could mean treating more patients without sacrificing effectiveness. The trial was officially registered with ICMR under number CTRI/2022/05/042781.